

MEDIA RELEASE

MCAZ ISSUES A CLASS II RECALL FOR A BATCH OF YAZ PLUS CONTRACEPTIVES DUE TO A QUALITY ISSUE

Embargo: Immediate Release

Harare, 22 November 2024 – The Medicines Control Authority of Zimbabwe (MCAZ) wishes to inform all stakeholders of a **Class II Recall** up to the consumer level of **YAZ PLUS TABLETS, REG. NO.: 2022/21.2.1/6235, BATCH: WEW961J**, manufactured by **BAYER (PTY) LTD, SOUTH AFRICA**.

The affected batch of YAZ Plus tablets is being recalled because some packs were found to contain **24 light orange hormone-free tablets** and **4 pink hormone tablets** instead of the correct configuration of **24 pink hormone tablets** and **4 light orange hormone-free tablets**.

Non-compliance with product quality specifications may result in loss of efficacy and potential harm to patients. This recall is a precautionary measure to protect the public from the possible inefficacy of the affected batch.


MCAZ advises all licensed wholesalers, pharmacies, public and private clinics, and hospitals to quarantine any affected units of the product and to cooperate fully with Bayer (Pty) Ltd and the local distributors of the product in Zimbabwe during the recall process.

Members of the public using this contraceptive are urged to check the batch number on their tablet packs. If they have the affected batch, they should immediately stop using the tablets, return the affected packs to their pharmacist, and consult with their healthcare professional.

See examples of correct and incorrect tablet packaging.



Incorrect blister



Correct blister

Issued by:

Mr. Richard T Rukwata
Director – General
mcaz@mcaz.co.zw

For further enquiries /information contact:

MCAZ Media contact:

Mr. Davison Kaiyo

Public Relations Officer

Cell: +263782788568/+263733862742

E-mail: dkaiyo@mcaz.co.zw , mcaz@mcaz.co.zw

About MCAZ:

Medicines Control Authority of Zimbabwe (MCAZ) is a statutory body established by an Act of Parliament, The Medicines and Allied Substances Control Act (MASCA) [Chapter 15.03]. MCAZ is a successor of the Drugs Control Council (DCC) and the Zimbabwe Regional Drug Control Laboratory (ZRDCL). DCC was established by an Act of Parliament in 1969: Drugs and Allied Substances Control Act [Chapter 15.03] following which ZRDCL became operational in 1989.

MCAZ is responsible for protecting public and animal health by ensuring that accessible medicines and allied substances and medical devices are safe, effective and of good quality through enforcement and adherence to standards by manufacturers and distributors.

The Medicines Control Authority of Zimbabwe (MCAZ), which is the National Pharmacovigilance Centre of Zimbabwe, is a participating country of the WHO International Drug Monitoring Program since 1998. The National Pharmacovigilance Centre is responsible for monitoring the safety of medical products and allied substances in Zimbabwe.

The mandate of MCAZ is to protect public health ensuring that medicines and medical devices on the market are safe, effective, and of good quality.

Notes to Editors:

MCAZ will post this media release on our website. Navigate to the Publications section on the website.

Should you request an interview for television, please send your request to mcaz@mcaz.co.zw and copy dkaiyo@mcaz.co.zw . Include your discussion points in your request.

Updates on licences, registrations can be accessed here: www.mcaz.co.zw/documents